iDNA Genomics Public (CYS:IDNA) Additional Paid-In Capital : €0.00 Mil(As of . 20)

View and export this data going back to 2021. Start your Free Trial

What is iDNA Genomics Public Additional Paid-In Capital?

iDNA Genomics Public Additional Paid-In Capital Historical Data

The historical data trend for iDNA Genomics Public's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iDNA Genomics Public Additional Paid-In Capital Chart

iDNA Genomics Public Annual Data

Trend

Additional Paid-In Capital

iDNA Genomics Public Semi-Annual Data

Additional Paid-In Capital

iDNA Genomics Public Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

iDNA Genomics Public Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of iDNA Genomics Public's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

iDNA Genomics Public Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » iDNA Genomics Public Ltd (CYS:IDNA) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

Evrota 25- 27, Kifissia, GRC, 145 64

Website

https://www.idnagenomics.com

iDNA Genomics Public Ltd is engaged in performing precision medicine and genetic analysis (DNA Tests). Its focus is on developing and providing Genetic Testing Analysis both in Medical and Direct-To-Consumer Genomics sectors, with research activity through cooperation with universities in Greece and abroad.